This is a reminder that most of the remaining HHS-supplied JYNNEOS doses will expire on Thursday, Oct. 31, 2024. Here’s more information and resources:
Novavax doses that expire on 10/31/24 will expire on that date.
Novavax vaccine being distributed has an expiry of 11/30/24. Novavax will be requesting a shelf-life extension for doses that have an expiry of 11/30/24 and beyond during the season. An Expiration Look-up Tool is available for providers to check for most up-to-date information about expiry before administration. The tool is accessible via QR code on vaccine carton and here.
CDC will continue to distribute Novavax vaccine up until 18 days before expiry. To minimize vaccine wastage, we encourage placing smaller, more frequent orders and limiting quantities to the amount of vaccine that can be utilized within a two-week period.
AVP COVID-19 vaccine remains available to order for all AVP providers in the IIS. Providers may choose to request Moderna, Pfizer, and/or Novavax.
Eligibility for AVP COVID-19 vaccine includes both uninsured and underinsured adults.
ACIP PCV21 Recommendations Published in MMWR
CDC recently published Use of 21-Valent Pneumococcal Conjugate Vaccine among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices—United States, 2024.
Below is a brief summary:
-
PCV21 (Capvaxive, Merck) is an option for adults aged ≥19 years who are currently recommended to receive PCV15 or PCV20. PCV21 contains eight serotypes not included in other licensed vaccines.
- If PCV20 or PCV21 is used, a dose of PPSV23 isn't needed for adults 65 years and older who never received any pneumococcal vaccine.
- Unlike PCV15 (Vaxneuvance, Merck) and PCV20 (Prevnar 20, Pfizer), which are routinely recommended for children, PCV21 does not provide protection against certain serotypes responsible for a significant burden of disease in children. For this reason, PCV21 is not licensed or recommended for use in children.
Additional resources:
Be on the lookout for upcoming updates in response to the latest ACIP meeting.
On October 17, CDC released updated VISs for the COVID-19 vaccine, and RSV vaccine. CDC encourages providers to begin using these immediately.
|